ORCID
- J Robert Sneyd: 0000-0003-3546-9856
Abstract
Goyal and colleagues share a large US health system’s experience of 9,431 cases of real-world remimazolam use, offering insight into current practice patterns, recovery times, and accurate adverse event rates. The authors report rapid recovery after remimazolam, including shorter time to Post-Anaesthesia Care Unit (PACU) discharge readiness and faster return to baseline Richmond Agitation-Sedation Scale following flumazenil administration, with a critical event rate of 0.7%. Interesting practice patterns were observed, including frequent co-administration with other anesthetics rather than as a sole agent. Although only licensed for procedural sedation in the US, the authors reported extensive use of remimazolam to induce anaesthesia, especially for patients of ASA physical status 3-5. This editorial highlights the disconnect between the development of remimazolam and its practical clinical use, as well as the work still needed to clarify the agent’s optimal role.
DOI Link
Publication Date
2026-06-17
Publication Title
BJA Open
Acceptance Date
2026-04-22
Deposit Date
2026-04-22
Additional Links
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Wingert, T., & Sneyd, J. (2026) 'Rethinking remimazolam: reconciling regulatory positioning with clinical reality', BJA Open, . Available at: 10.1016/j.bjao.2026.100567
